Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification--preliminary results.

PURPOSE To investigate whether there is any correlation between standard efficacy endpoints-specifically, tumor response, progression-free survival, and overall survival-and tumor perfusion parameters measured by using dynamic contrast material-enhanced ultrasonography (US) in patients with advanced hepatocellular carcinoma (HCC) treated with bevacizumab. MATERIALS AND METHODS The institutional review board approved the study, and all patients provided written informed consent before their enrollment. Between June 3, 2005, and September 28, 2007, 42 patients (33 men, nine women; median age, 62 years; age range, 23-84 years) participated in this phase II study of single-agent bevacizumab treatment. Tumor response (based on RECIST [response evaluation criteria in solid tumors]) at 2 months was assessed in 37 patients, and progression-free survival and overall survival were assessed in all 42 patients. Dynamic contrast-enhanced US (ie, dynamic US) was performed before treatment (day 0); on days 3, 7, 14, and 60 after treatment; and every 2 months thereafter. Tumor perfusion parameters were estimated quantitatively from contrast material uptake curves constructed from raw linear data. The changes in dynamic US functional parameters between day 0 and the later time points were compared between treatment responders and nonresponders by using nonparametric tests. Given multiple comparisons, P < .001 indicated significance. RESULTS The percentage decrease in several dynamic US parameters between day 0 and day 3 showed trends toward correlation with (a) tumor response in terms of total area under the time-intensity curve (AUC) (P = .02), AUC during wash in (P = .04), AUC during washout (P = .02), and time to peak intensity (P = .03); (b) progression-free survival in terms of time to peak intensity (P = .028); and (c) overall survival in terms of AUC (P = .002) and AUC during washout (P = .003). CONCLUSION Dynamic US can be used to quantify dynamic changes in tumor vascularity as early as 3 days after bevacizumab administration in patients with HCC. These early changes in tumor perfusion may be predictive of tumor response at 2 months, progression-free survival, and overall survival, and they may be potential surrogate measures of the effectiveness of antiangiogenic therapy in patients with HCC.

[1]  J. Pignon,et al.  Bevacizumab in patients (pts) with advanced hepatocellular carcinoma (HCC): Preliminary results of a phase II study with circulating endothelial cell (CEC) monitoring , 2007 .

[2]  J. G. Mottley,et al.  Volumetric arterial flow quantification using echo contrast. An in vitro comparison of three ultrasonic intensity methods: radio frequency, video and Doppler. , 1993, Ultrasound in medicine & biology.

[3]  J. Soria,et al.  Functional imaging using DCE-US: Which parameter for the early evaluation of antiangiogenetic therapies? , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Alona Muzikansky,et al.  Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  P. Vrignaud,et al.  Early Quantitative Evaluation of a Tumor Vasculature Disruptive Agent AVE8062 Using Dynamic Contrast-Enhanced Ultrasonography , 2008, Investigative radiology.

[6]  G. Benea,et al.  Effect of Angiosonography to Monitor Response During Imatinib Treatment in Patients with Metastatic Gastrointestinal Stromal Tumors , 2005, Clinical Cancer Research.

[7]  P. Opolon,et al.  Evaluation of Contrast-Enhanced Color Doppler Ultrasound for the Quantification of Angiogenesis In Vivo , 2001, Investigative radiology.

[8]  G. Seidel,et al.  Quantification of flow rates using harmonic grey-scale imaging and an ultrasound contrast agent: an in vitro and in vivo study. , 2001, Ultrasound in medicine & biology.

[9]  Christoph F Dietrich,et al.  Quantitative contrast enhanced ultrasound of the liver for time intensity curves-Reliability and potential sources of errors. , 2010, European journal of radiology.

[10]  N. Lassau,et al.  Évaluation de l’angiogénèse tumorale à l’aide de l’échographie de contraste , 2009 .

[11]  P A Heidenreich,et al.  In vitro calculation of flow by use of contrast ultrasonography. , 1993, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[12]  Natalia Mendelev,et al.  Vascular density and VEGF expression in hepatic lesions. , 2007, Journal of gastrointestinal and liver diseases : JGLD.

[13]  Sheng-Nan Lu,et al.  Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patients , 2008, Journal of surgical oncology.

[14]  J. Soria,et al.  Phase I Trial of Sorafenib in Combination with IFN α-2a in Patients with Unresectable and/or Metastatic Renal Cell Carcinoma or Malignant Melanoma , 2007, Clinical Cancer Research.

[15]  N. Mulder,et al.  Early prediction of response to sorafenib treatment in patients with hepatocellular carcinoma (HCC) with 18F- fluorodeoxyglucose-positron emission tomography (18F-FDG-PET) , 2008 .

[16]  D. Cosgrove,et al.  Contrast Ultrasonography: Necessity of Linear Data Processing for the Quantification of Tumor Vascularization , 2010, Ultraschall in der Medizin.

[17]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[18]  M. Rosen,et al.  Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): A phase II study , 2007 .

[19]  N. Holalkere,et al.  Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma. , 2008, The oncologist.

[20]  P. Terrier,et al.  Doppler US with perfusion software and contrast medium injection in the early evaluation of isolated limb perfusion of limb sarcomas: prospective study of 49 cases. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  F. Izzo,et al.  A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients , 1998, Hepatology.

[22]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[23]  Chiung-Nien Chen,et al.  Effect of thalidomide in hepatocellular carcinoma: assessment with power doppler US and analysis of circulating angiogenic factors. , 2005, Radiology.

[24]  Linda Chami,et al.  Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography. , 2006, AJR. American journal of roentgenology.

[25]  J. Correas,et al.  Infusion versus bolus of an ultrasound contrast agent: in vivo dose-response measurements of BR1. , 2000, Investigative radiology.

[26]  S. Rafii,et al.  Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Linda Chami,et al.  Dynamic contrast-enhanced ultrasonography (DCE-US) with quantification of tumor perfusion: a new diagnostic tool to evaluate the early effects of antiangiogenic treatment , 2007, European radiology.

[28]  B. Daniele,et al.  Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma , 2008 .

[29]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[30]  Wei Wu,et al.  Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma. , 2005, Hepatobiliary & pancreatic diseases international : HBPD INT.

[31]  Linda Chami,et al.  To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. , 2006, European journal of cancer.

[32]  Roberto Delfini,et al.  Semiquantitative Human Cerebral Perfusion Assessment With Ultrasound in Brain Space‐Occupying Lesions , 2008, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[33]  A. Cheng,et al.  Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma , 2010, British Journal of Cancer.